Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06840886 · ClinicalTrials.gov registry record · Phase 1

A Study of PHST001 in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Pheast Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
155
Enrollment target
10
Study locations

NCT06840886 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Pheast Therapeutics. The registered enrollment target is 155 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06840886, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Pheast Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
155 participants
Enrollment target
10
Study locations

Study Summary

PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG PHST001

Study Locations (10)

California

  • USC Norris Comprehensive Cancer Center - Los Angeles
  • Stanford University School of Medicine - Palo Alto

Texas

  • MD Anderson Cancer Center - Houston
  • South Texas Accelerated Research Therapeutics (START) - San Antonio

Connecticut

  • Yale Cancer Center - New Haven

Illinois

  • University of Chicago Medical Center - Chicago

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • University of Michigan Rogel Cancer Center - Ann Arbor

North Carolina

  • Duke Cancer Institute - Durham

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 155 participants
Start Date 2025-03-31
Est. Completion 2031-04
Phase Phase 1

Sponsor

Pheast Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06840886

The ClinicalTrials.gov registry entry for NCT06840886 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower). The listed sponsor is Pheast Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PHST001 is the first listed.

NCT06840886 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Texas, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06840886 about?

NCT06840886 is a clinical study titled "A Study of PHST001 in Advanced Solid Tumors". PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to ev...

What is the current status of trial NCT06840886?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2025-03-31. Estimated completion is 2031-04.

What conditions does trial NCT06840886 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06840886?

The interventions under investigation include: PHST001 (DRUG).

Who is sponsoring clinical trial NCT06840886?

This trial is sponsored by Pheast Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06840886 being conducted?

This trial has 10 study locations across California, Connecticut, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.